生技药品合约开发市场按服务类型、分子类型、治疗领域、宿主系统、最终用户和技术划分－2025-2032年全球预测

预计到 2032 年，生技药品合约开发市场将成长至 182.9 亿美元，复合年增长率为 12.15%。

为高阶主管提供生技药品合约开发领域的最新动态，阐明技术、监管和采购选择的策略重点。

生技药品合约开发领域正经历重大变革，其驱动力包括科学创新、不断变化的监管环境以及研发和生产能力获取与部署方式的重新配置。本文将重点在于阐述塑造该产业的核心动态，并阐明经营团队必须纳入短期规划和长期能力建构的策略考量。它强调了技术进步、供应链韧性以及内部研发与外包伙伴关係之间不断变化的平衡之间的相互关係。

随着包括日益复杂的单株抗体结构以及先进的细胞和基因疗法在内的新型治疗方法的出现，製程要求和设施设计正在改变。同时，製造商和研发人员面临着产品品质、可比性和法规合规性方面日益严格的审查，这使得经验丰富的合约研究合作伙伴的价值日益凸显，他们能够在缩短研发週期的同时规避技术风险。因此，企业领导者必须重新评估筹资策略，优先选择能够提供涵盖製程开发、临床生产和商业化规模生产的端到端解决方案的合作伙伴。

此做法承认宏观经济和政策因素与实际营运情况相互交织。贸易政策的变化、区域奖励以及资本配置模式都会影响产能扩张的地点以及哪些技术会获得优先投资。这些因素共同作用，既创造了差异化发展的机会，也带来了加速能力发展的压力。以下章节将更详细地分析这些变化，以帮助经营团队在寻求保持生技药品研发和商业化势头时做出切合实际的选择。

积极考虑影响生技药品受託製造的技术、商业性和结构性变化。

生技药品研发生态系统正经历技术、商业性和结构上的变革，这些变革正在改变整个价值链的竞争格局。在技​​术方面，连续生产方法和一次性系统的应用正在重新定义製程架构和设施布局，从而实现更大的产能弹性和更快的产品宣传活动切换。这些技术变革，加上更复杂的上游和下游研发技术，需要整合製程知识和能力，以确保大规模生产中品质属性的一致性。

在商业性，细胞和基因疗法等复杂治疗方法的兴起，推动了对与客製化研发路径紧密结合的临床生产服务的需求。这使得能够提供生产能力以及深厚的监管和分析专业知识的合作伙伴的战略重要性日益凸显。同时，支付方的监控和生命週期管理策略正促使申办方从研发初期就重新评估其商业化计划，并倾向于选择与长期产品策略相契合的合约合作伙伴，而非交易型供应商。

从结构上看，特定领域的整合以及利基专业供应商的成长正在重塑供应商格局。能够提供整合製程开发、多阶段临床生产支援以及快速扩大规模实现商业化生产的企业将拥有竞争优势。同时，地缘政治的不确定性和供应链的脆弱性促使企业重新关注区域多元化和关键能力的近岸外包。总而言之，这些变革性的变化要求企业领导者重新评估伙伴关係，选择性地投资策略技术，并建立适应性强的管治模式，以应对复杂性并加快产品进入临床和市场的速度。

2025年美国关税调整将如何改变生技药品研发采购、供应链设计与位置决策的详细分析

2025年实施的额外关税和贸易政策调整，为参与生技药品合约开发的机构带来了新的营运和策略考量。关税变化将影响专用设备、一次性组件和关键原材料的进出口，可能增加采购计划的复杂性，并要求更稳健的供应商多元化策略。因此，製造商和赞助商将重新审视其供应商组合和库存政策，以保护其研发项目免受关税波动的影响。

除了直接的成本影响外，关税还会影响生产地点和资本配置的决策。鑑于成本结构和海关程序的变化，必须重新评估某些地区在设备和耗材采购方面的比较优势。拥有灵活生产架构（例如模组化设备部署和可适应的製程平台）的公司更有能力适应这些变化。此外，关税驱动的供应链变化凸显了熟悉当地法规的成熟物流管道的重要性，这些管道可以缩短生技药品製品跨境运输的前置作业时间和降低相关营运风险。

监管和合约框架也需要更加密切关注。服务协议和供应商合约可能需要重新谈判，以纳入关税转嫁条款、前置作业时间调整、紧急条款等内容。因此，产业领导者正在加强跨职能团队建设，包括采购、法律、监管和营运方面的专家，以确保对关税的影响做出协调一致的应对。总之，虽然关税不会改变生技药品研发的基本科学挑战，但它们确实会重塑采购、生产力计画和长期策略投资的经济效益和风险状况。

透过全面的细分主导洞察，揭示服务类型、分子类别、治疗领域、宿主系统、最终用户和实行技术方面的能力差距和策略重点。

透过细緻的细分视角，我们可以揭示服务类型、分子类别、治疗领域、宿主系统、最终用户和赋能技术等方面的能力差距和策略机会所在。按服务类型划分，市场涵盖临床生产、商业化生产、填充和製程开发，其中临床生产本身包括I期、II期和III期临床试验，而製程开发则分为下游开发和上游开发。这种细分凸显了合作伙伴的重要性，该合作伙伴能够无缝推进计划，从早期工艺表征到后期放大生产，再到最终的商业化生产，确保分析方法、可比性策略和品质系统的连续性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 采用一次性反应器技术可提高生物製药生产的灵活性并降低污染风险
• 利用模组化CDMO设施扩展细胞和基因治疗生产服务，实现快速临床规模化生产
• 在生物製药生产中应用连续层析法和灌註生物工艺，以提高生产效率和成本效益。
• 将人工智慧和机器学习整合到预测建模和流程开发中，以加速生物候选药物的筛选
• 针对mRNA疫苗和基因疗法的专业填充和包装服务日益增长，这些服务对低温运输要求非常严格。
• 加强区域合约生产商与生物技术公司之间的合作，以应对复杂的全球生物製药监管环境
• 投资绿色生物製造倡议和永续实践，以减少生物製药生产对环境的影响
• 实施数位双胞胎技术和即时分析，实现端到端生物製药供应链的可视性和风险管理
• 专注于生物相似药的CDMO（合约研发生产机构）的出现，为下一代治疗性抗体提供先进的糖基化工程服务。
• 整合基于区块链的溯源解决方案，以确保生技药品血清采购的透明度和合规性。

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章生技药品合约开发市场（按服务类型划分）

• 临床生产
  • 第一阶段
  • 第二阶段
  • 第三阶段
• 商业製造
• 填充和精加工
• 製程开发
  • 下游开发
  • 上游开发

第九章生技药品合约开发市场（依分子类型划分）

• 细胞和基因治疗
• 单株抗体
  • 双重特异性
  • 共轭物
  • 裸
• 重组蛋白
• 疫苗
  • 细菌
  • mRNA
  • 病毒

第十章生技药品合约开发市场（依治疗领域划分）

• 自体免疫疾病
• 心血管系统
• 感染疾病
  • 细菌
  • 病毒
• 肿瘤学
  • 血液学
  • 固态肿瘤

第十一章生技药品合约开发市场（依宿主系统划分）

• 哺乳动物
  • Cho 细胞
  • Ns0细胞
• 微生物
  • 大肠桿菌
• 酵母菌

第十二章生技药品合约开发市场（依最终用户划分）

• 生物製药公司
• 契约製造组织
• 製药公司

第十三章生技药品合约开发市场（依技术划分）

• 连续製造
  • 灌注
  • 单一途径
• 免洗系统
• 不銹钢系统

第十四章生技药品合约开发市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章生技药品合约开发市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章 各国生技药品合约开发市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Lonza Group Ltd
  • Catalent, Inc
  • Thermo Fisher Scientific Inc
  • Samsung Biologics Co., Ltd
  • Boehringer Ingelheim International GmbH
  • WuXi Biologics Ltd
  • Fujifilm Diosynth BIoTechnologies USA, Inc
  • AGC Biologics A/S
  • Recipharm AB
  • Rentschler Biopharma SE

The Biologics Contract Development Market is projected to grow by USD 18.29 billion at a CAGR of 12.15% by 2032.

An executive introduction to the evolving biologics contract development landscape that frames strategic priorities across technology, regulation, and sourcing choices

The biologics contract development landscape is undergoing a profound transformation driven by scientific innovation, evolving regulatory expectations, and a reconfiguration of how development and manufacturing capacity are sourced and deployed. This introduction synthesizes the core dynamics shaping the sector, framing the strategic considerations that executive teams must integrate into near-term planning and longer-term capability building. It clarifies the interplay between technological advances, supply chain resilience, and the shifting balance between in-house development and outsourced partnerships.

Emerging therapeutic modalities, including advanced cell and gene therapies alongside increasingly complex monoclonal antibody constructs, are altering process demands and facility designs. Concurrently, manufacturers and developers face heightened scrutiny around product quality, comparability, and regulatory compliance, which in turn elevates the value of experienced contract development partners who can navigate technical risk while compressing timelines. As a result, leaders must reassess sourcing strategies to prioritize partners capable of delivering end-to-end solutions spanning process development, clinical manufacturing, and commercial-scale production.

This introduction also recognizes the macroeconomic and policy factors that intersect with operational realities. Trade policy shifts, regional incentives, and capital allocation patterns will influence where capacity is expanded and what technologies receive preferential investment. Together, these forces create both opportunities for differentiation and pressure to accelerate capability development. The following sections unpack these shifts in greater detail to inform pragmatic choices for executives seeking to sustain momentum in biologics development and commercialization.

A forward-looking examination of the technical, commercial, and structural transformations reshaping contract development and manufacturing for biologics

The biologics development ecosystem is experiencing transformative shifts that are simultaneously technical, commercial, and structural, altering competitive positioning across the value chain. On the technical front, continuous manufacturing approaches and single-use system adoption are redefining process architectures and facility footprints, enabling greater flexibility in capacity utilization and faster changeovers between product campaigns. These technology shifts coincide with more sophisticated upstream and downstream development techniques that demand integrated process knowledge and capability to ensure consistent quality attributes at scale.

Commercially, the rise of complex modalities such as cell and gene therapies has expanded demand for bespoke development pathways and tightly coordinated clinical manufacturing services. This has elevated the strategic importance of partners that can provide not only manufacturing capacity but also deep regulatory and analytical expertise. In parallel, payer scrutiny and lifecycle management strategies are prompting sponsors to rethink commercialization plans early in development, which favors contract partners aligned to long-term product strategies rather than transactional suppliers.

Structurally, consolidation among certain segments and the growth of specialist niche providers are reshaping the supplier landscape. Firms that can offer integrated process development, clinical manufacturing support across multiple phases, and rapid scale-up to commercial manufacturing will hold a competitive edge. Meanwhile, geopolitical uncertainty and supply chain fragility are driving a renewed focus on regional diversification and nearshoring of critical capabilities. Taken together, these transformative shifts require leaders to re-evaluate partnerships, invest selectively in strategic technologies, and build adaptive governance models to manage complexity and accelerate time to clinic and market.

An in-depth analysis of how the 2025 United States tariff adjustments alter procurement, supply chain design, and location decisions for biologics development

The introduction of additional tariff measures and trade policy recalibrations in 2025 has introduced new operational and strategic considerations for organizations engaged in biologics contract development. Tariff changes affect inbound and outbound flows of specialized equipment, single-use components, and critical raw materials, which can increase the complexity of procurement planning and necessitate more robust supplier diversification strategies. Consequently, manufacturers and sponsors are reassessing vendor portfolios and inventory policies to insulate development programs from tariff-driven volatility.

Beyond direct cost implications, tariffs influence decisions about manufacturing location and capital deployment. Assumptions about the comparative advantage of particular regions for sourcing equipment or consumables must be revisited in light of altered cost structures and customs procedures. Firms with flexible manufacturing architectures, including capabilities for modular facility deployment and adaptable process platforms, are better positioned to respond to these shifts. Moreover, tariff-driven changes to supply chains amplify the importance of local regulatory familiarity and established logistics pathways, which can reduce lead times and the operational risks associated with cross-border movement of biologics materials.

Regulatory and contractual frameworks also require closer attention. Service agreements and supplier contracts may need renegotiation to account for tariff pass-through clauses, lead-time adjustments, and contingency provisions. Industry leaders are therefore strengthening cross-functional teams that include procurement, legal, regulatory, and operations professionals to ensure coherent responses to tariff impacts. In sum, while tariffs do not alter the fundamental scientific challenges of biologics development, they reshape the economics and risk profile of sourcing, capacity planning, and long-term strategic investments.

Comprehensive segmentation-driven insights that reveal capability gaps and strategic priorities across service types, molecule classes, therapeutic areas, host systems, end users, and enabling technologies

A nuanced segmentation lens reveals where capability gaps and strategic opportunities converge across service types, molecule classes, therapeutic areas, host systems, end users, and enabling technologies. Based on service type, the market encompasses clinical manufacturing, commercial manufacturing, fill-finish, and process development; clinical manufacturing itself spans Phase I, Phase II, and Phase III, while process development divides into downstream development and upstream development. This segmentation highlights the need for partners who can move projects seamlessly from early-phase process characterization through late-stage scale-up and commercial transfer, ensuring continuity of analytical methods, comparability strategies, and quality systems.

Based on molecule type, the landscape includes cell and gene therapies, monoclonal antibodies, recombinant proteins, and vaccines; within monoclonal antibodies, bispecific, conjugated, and naked formats present varying process and analytical challenges, and vaccines differentiate across bacterial, mRNA, and viral platforms. These distinctions drive divergent technical requirements-cell and gene therapies require specialized viral vector production and cold chain logistics, bispecific antibodies often demand advanced purification and potency assays, and mRNA vaccines hinge on lipid nanoparticle formulation and stringent RNA integrity controls-thereby influencing supplier capability priorities and facility design.

Based on therapeutic area, the market covers autoimmune disorders, cardiovascular, infectious diseases, and oncology; infectious diseases further split into bacterial and viral categories, while oncology divides into hematology and solid tumors. Therapeutic focus affects clinical manufacturing cadence, batch sizes, and development timelines; oncology programs, particularly in hematology, may require rapid iterative production for personalized therapies, whereas infectious disease vaccine campaigns often prioritize surge capacity and platform scalability.

Based on host system, host options include mammalian, microbial, and yeast; mammalian systems further specify CHO cells and NS0 cells, and microbial systems highlight E. coli. Host selection informs upstream process configuration, contamination control regimes, and downstream purification strategies, with mammalian hosts typically used for complex glycosylated proteins and microbial hosts offering cost-effective expression for certain recombinant products.

Based on end user, the market serves biopharmaceutical companies, contract manufacturing organizations, and pharmaceutical companies; understanding end-user needs clarifies service packaging, from flexible clinical supply arrangements for small biotech sponsors to integrated, regulatory-ready commercial supply chains for larger developers. Finally, based on technology, capabilities range across continuous manufacturing, single-use systems, and stainless steel systems, with continuous manufacturing itself encompassing perfusion and single-pass modalities. Technology selection affects facility footprint, capital intensity, and operational throughput, and it often determines the speed at which a partner can support transitions between clinical and commercial phases. Collectively, these segmentation dimensions underscore the imperative for strategic alignment between sponsor programs and partner capabilities to minimize technical risk and optimize development timelines.

Strategic regional intelligence that maps capacity strengths, regulatory nuances, and supply chain advantages across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape where biologics development activities concentrate and how organizations structure their global operations. In the Americas, innovation hubs and a dense ecosystem of clinical trials create sustained demand for clinical manufacturing and rapid analytics, while regulatory frameworks emphasize data integrity and process validation practices that support accelerated development pathways. This region also benefits from proximity to major sponsors and venture capital, which reinforces a pipeline of early-stage programs requiring specialized contract development support.

Europe, the Middle East & Africa features diverse regulatory environments and a mix of established biomanufacturing clusters alongside emerging capabilities. In several European markets, incentives for bioproduction and investments in advanced manufacturing infrastructure support the adoption of continuous processing and single-use technologies. Regional collaboration initiatives and harmonization efforts can reduce barriers for cross-border supply, but organizations must still navigate differing national requirements and logistics complexities when planning multi-site development and commercial supply strategies.

Asia-Pacific continues to expand its role as both a manufacturing base and an innovation center, with notable growth in contract manufacturing capacity, investments in single-use systems, and an increasing number of facilities certified to international regulatory standards. The region's supply chain strengths, including components and consumables manufacturing, offer advantages for sponsors seeking diversified sourcing and competitive cost structures. However, regulatory pathways and market access conditions vary substantially across jurisdictions, prompting sponsors and contract developers to build localized regulatory expertise and regional partnerships to ensure timely program progression and compliance.

Across regions, strategic choices will hinge on balancing access to talent, regulatory alignment, supply chain resilience, and proximity to clinical trial networks. Firms that develop regional playbooks tailored to these considerations will be better positioned to support sponsors across development stages and to respond to shifting policy and economic environments.

Critical competitive insights into how technology investment, regulatory depth, and geographic footprint create differentiation among contract development and manufacturing organizations

Competitive dynamics among contract development and manufacturing organizations are defined by differentiation in technology platforms, depth of regulatory experience, and the breadth of integrated services offered. Leading providers prioritize investments in advanced analytics, scalable single-use systems, and process intensification techniques to reduce cycle times and improve product quality consistency. These investments are often complemented by strategic partnerships and capability co-development arrangements that accelerate access to novel modalities and analytical methods.

Another axis of differentiation lies in quality systems and regulatory track records. Organizations with established compliance histories across major regulatory jurisdictions can facilitate smoother program transitions from clinical phases to commercial supply, which is particularly valuable for sponsors seeking global launches. In addition, providers that offer value-added services-such as comparability study design, stability testing strategies, and regulatory submission support-are increasingly preferred over purely transactional suppliers because they reduce coordination overhead and technical risk for sponsors.

Operational resilience and geographic footprint also play a critical role. Firms with multi-site capabilities can offer redundancy and surge capacity, which is crucial for vaccine programs or personalized therapies requiring rapid turnarounds. At the same time, niche specialists focused on particular modalities or host systems carve out defensible positions by developing deep technical expertise and proprietary process knowledge. Collectively, these strategic approaches define the competitive map and inform how sponsors select partners based on alignment to program complexity, timeline urgency, and long-term commercialization plans.

Actionable strategic recommendations for industry leaders to align technology investments, operational resilience, and partnership models for scalable biologics development

Industry leaders must adopt actionable strategies that reconcile innovation velocity with operational robustness to capture value in biologics development. First, prioritize technology roadmaps that balance continuous processing and single-use flexibility with selective investments in stainless steel systems where long-term high-volume production justifies the capital outlay. Align these technology choices with product portfolios and anticipated lifecycle requirements to avoid stranded assets and ensure scalable capacity.

Second, build cross-functional governance mechanisms that bring procurement, quality, regulatory, and operations together early in program planning. This integrated approach reduces handoff risks, shortens decision cycles, and creates clearer escalation paths for technical issues. Third, enhance supplier diversity by qualifying alternate vendors for critical consumables and equipment, and by establishing regional sourcing strategies that mitigate tariff and logistics exposures. Combined with scenario-based inventory strategies, these actions strengthen supply chain resilience.

Fourth, invest in talent and process knowledge transfer programs that accelerate sponsor-partner integration, particularly for complex modalities such as cell and gene therapies and novel antibody constructs. This includes structured training, collaborative development sprints, and shared analytics platforms that preserve institutional knowledge and enable rapid troubleshooting. Finally, adopt partnership models that align incentives around long-term product success, including risk-sharing arrangements for scale-up and commercialization phases. These practical steps will enable organizations to reduce technical risk, accelerate timelines, and capture strategic value from emerging biologics opportunities.

A transparent, multi-source research methodology combining expert interviews, technical literature synthesis, and operational assessment to ensure actionable analysis

The research approach underpinning this analysis combines qualitative expert interviews, technical literature synthesis, and cross-functional operational assessment to ensure a robust and actionable perspective. Primary inputs included discussions with process development scientists, manufacturing leaders, regulatory affairs professionals, and supply chain experts, which provided firsthand insight into current pain points, technology adoption patterns, and regional operational differences. These conversations were structured to surface both tactical challenges and strategic imperatives across clinical and commercial stages.

Secondary research focused on technical publications, regulatory guidance documents, and publicly available case studies that illustrate best practices in process intensification, facility design, and quality systems. Emphasis was placed on triangulating findings across sources to validate trends and to identify areas of divergence between reported capabilities and operational realities. Analytical frameworks were applied to assess technology maturity, supply chain exposure, and the alignment of end-user needs with provider offerings.

Throughout the research process, care was taken to ensure transparency of assumptions and to document methodological limitations. Where gaps existed in public information, targeted expert validation helped refine interpretations and reduce uncertainty. The result is a synthesis that balances technical rigor with practical relevance, providing executives with clear diagnostic insight and a tested set of strategic considerations to guide decision-making in biologics contract development.

A conclusive synthesis highlighting imperative focus areas for leaders to secure resilient, scalable, and commercially viable biologics development pathways

In conclusion, the biologics contract development environment is at an inflection point where technological innovation, regulatory complexity, and geopolitical shifts converge to reshape strategic decision-making. Sponsors and providers who align technology investments with product modality demands, who strengthen cross-functional governance, and who diversify supply chains will navigate this period with greater agility and lower operational risk. The ability to integrate process development, clinical manufacturing, and commercial readiness into cohesive program plans will determine which organizations accelerate timelines and capture value.

Looking ahead, success will favor those who adopt adaptive facility designs, invest in advanced analytics, and cultivate partnerships that share both expertise and risk. Regional strategies should be calibrated to regulatory realities and supply chain advantages, and contingency planning should account for policy-driven disruptions such as tariff adjustments. By focusing on these core imperatives, industry leaders can translate emerging trends into durable competitive advantage and ensure resilient pathways from discovery through commercial supply.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Adoption of single-use bioreactor technology to enhance flexibility and reduce contamination risks in biologics manufacturing
• 5.2. Expansion of cell and gene therapy manufacturing services through modular CDMO facilities for rapid clinical scale-up
• 5.3. Implementation of continuous chromatography and perfusion bioprocessing for increased productivity and cost efficiencies in biologics production
• 5.4. Integration of AI and machine learning in process development for predictive modeling and accelerated biologic candidate selection
• 5.5. Growth of specialized fill-finish services tailored for mRNA vaccines and gene therapies with stringent cold chain requirements
• 5.6. Rising collaborations between regional CMOs and biotech firms to navigate complex global biologics regulatory pathways
• 5.7. Investment in green biomanufacturing initiatives and sustainable practices to reduce environmental impact of biologics production
• 5.8. Deployment of digital twin technology and real-time analytics for end-to-end biologics supply chain visibility and risk management
• 5.9. Emergence of biosimilar-focused CDMOs offering advanced glycoengineering services for next-generation therapeutic antibodies
• 5.10. Integration of blockchain-enabled traceability solutions to ensure transparency and compliance in biologics serum sourcing

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development Market, by Service Type

• 8.1. Clinical Manufacturing
  • 8.1.1. Phase I
  • 8.1.2. Phase II
  • 8.1.3. Phase III
• 8.2. Commercial Manufacturing
• 8.3. Fill Finish
• 8.4. Process Development
  • 8.4.1. Downstream Development
  • 8.4.2. Upstream Development

9. Biologics Contract Development Market, by Molecule Type

• 9.1. Cell Gene Therapy
• 9.2. Monoclonal Antibodies
  • 9.2.1. Bispecific
  • 9.2.2. Conjugated
  • 9.2.3. Naked
• 9.3. Recombinant Proteins
• 9.4. Vaccines
  • 9.4.1. Bacterial
  • 9.4.2. Mrna
  • 9.4.3. Viral

10. Biologics Contract Development Market, by Therapeutic Area

• 10.1. Autoimmune Disorders
• 10.2. Cardiovascular
• 10.3. Infectious Diseases
  • 10.3.1. Bacterial
  • 10.3.2. Viral
• 10.4. Oncology
  • 10.4.1. Hematology
  • 10.4.2. Solid Tumors

11. Biologics Contract Development Market, by Host System

• 11.1. Mammalian
  • 11.1.1. Cho Cells
  • 11.1.2. Ns0 Cells
• 11.2. Microbial
  • 11.2.1. E Coli
• 11.3. Yeast

12. Biologics Contract Development Market, by End User

• 12.1. Biopharmaceutical Companies
• 12.2. Contract Manufacturing Organizations
• 12.3. Pharmaceutical Companies

13. Biologics Contract Development Market, by Technology

• 13.1. Continuous Manufacturing
  • 13.1.1. Perfusion
  • 13.1.2. Single Pass
• 13.2. Single Use Systems
• 13.3. Stainless Steel Systems

14. Biologics Contract Development Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Biologics Contract Development Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Biologics Contract Development Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Lonza Group Ltd
  • 17.3.2. Catalent, Inc
  • 17.3.3. Thermo Fisher Scientific Inc
  • 17.3.4. Samsung Biologics Co., Ltd
  • 17.3.5. Boehringer Ingelheim International GmbH
  • 17.3.6. WuXi Biologics Ltd
  • 17.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc
  • 17.3.8. AGC Biologics A/S
  • 17.3.9. Recipharm AB
  • 17.3.10. Rentschler Biopharma SE

LIST OF FIGURES

• FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. BIOLOGICS CONTRACT DEVELOPMENT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. BIOLOGICS CONTRACT DEVELOPMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY DOWNSTREAM DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY UPSTREAM DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CELL GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BISPECIFIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONJUGATED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NAKED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY HOST SYSTEM, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY YEAST, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PERFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE PASS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SINGLE USE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY STAINLESS STEEL SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 283. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 284. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 285. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
• TABLE 286. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
• TABLE 287. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2018-2024 (USD MILLION)
• TABLE 288. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY CLINICAL MANUFACTURING, 2025-2032 (USD MILLION)
• TABLE 289. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT MARKET SIZE, BY PROCESS DEVELOPMENT, 201